Journal ArticleDOI
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
Bernard Escudier,Robert J. Motzer,Padmanee Sharma,John Wagstaff,Elizabeth R. Plimack,Hans J. Hammers,Frede Donskov,Howard Gurney,Jeffrey A. Sosman,Pawel Zalewski,Ulrika Harmenberg,David F. McDermott,Toni K. Choueiri,Martin Eduardo Richardet,Yoshihiko Tomita,Alain Ravaud,Justin Doan,Huanyu Zhao,Helene Hardy,Saby George +19 more
Reads0
Chats0
TLDR
A subset of patients with advanced renal cell carcinoma and disease progression may continue to benefit from nivolumab treatment beyond progression as evidenced by tumor reduction postprogression and an acceptable safety profile.About:
This article is published in European Urology.The article was published on 2017-09-01. It has received 187 citations till now. The article focuses on the topics: Nivolumab & Response Evaluation Criteria in Solid Tumors.read more
Citations
More filters
Journal ArticleDOI
Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte/macrophage infiltration into the clear cell renal cell carcinoma microenvironment
Wenhao Xu,Wangrui Liu,Yue Xu,Xi Tian,Aihetaimujiang Anwaier,Jia-Qi Su,Wen-Kai Zhu,Guohai Shi,Gaomeng Wei,Yong-Ping Huang,Yuan-Yuan Qu,Hailiang Zhang,Dingwei Ye +12 more
TL;DR: Wang et al. as mentioned in this paper identified the potential prognostic role of HK3 and provided clues about glycolysis and the microenvironmental characteristics of ccRCC cells.
Journal ArticleDOI
Role of noninvasive molecular imaging in determining response
TL;DR: Several experimental imaging-based strategies that are currently being explored to characterize in vivo immune responses are described and a growing body of preclinical data and nascent clinical experience with immuno-positron emission tomography molecular imaging is reviewed as a putative biomarker for cancer immunotherapy.
Journal ArticleDOI
Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
Journal ArticleDOI
Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma.
Matthew E. Tenold,Praful Ravi,Monika Kumar,I. Alex Bowman,Hans J. Hammers,Toni K. Choueiri,Primo N. Lara +6 more
TL;DR: The optimal management approach to advanced or metastatic renal cell cancer of the clear cell type continues to rapidly evolve and oncologists must think carefully when switching to another therapy, particularly in situations of drug intolerance or apparent disease progression.
Journal ArticleDOI
Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values.
TL;DR: The present review evaluated the results of randomized clinical trials for mRCC based on the effect size differences between treatments on relative scales and used second-generation p-values as a descriptive summary of the statistical evidence.
References
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal Article
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
Hirokazu Watanabe,Morihito Okada,Yasushi Kaji,Miyako Satouchi,Yozo Sato,Yuichiro Yamabe,Hiroaki Onaya,Masahiro Endo,Miyuki Sone,Yasuaki Arai +9 more
TL;DR: This paper is an overview of the new response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), with a focus on updated contents.
Journal ArticleDOI
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok,Axel Hoos,Steven J. O'Day,Jeffrey S. Weber,Omid Hamid,Céleste Lebbé,Michele Maio,Michael Binder,Oliver Bohnsack,Geoffrey M. Nichol,R. Humphrey,F. Stephen Hodi +11 more
TL;DR: Systematic criteria, designated immune-related response criteria, were defined in an attempt to capture additional response patterns observed with immune therapy in advanced melanoma beyond those described by Response Evaluation Criteria in Solid Tumors or WHO criteria.
Summary of product characteristics
Helen Andrew,Gemma Gossedge,Julie Croft,Neil Corrigan,Julia Brown,Nicholas West,Philip Quirke,Damian Tolan,Ronan A. Cahill,David Jayne +9 more
TL;DR: Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
Related Papers (5)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more